Dianthus Therapeutics Appoints New Director
Ticker: DNTH · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $40,000, $5,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, executive-compensation, governance
TL;DR
Dianthus adds Dr. Leff to the board, effective Sept 16, 2024.
AI Summary
Dianthus Therapeutics, Inc. announced on September 16, 2024, a change in its board of directors. Specifically, Dr. Jonathan Leff has been appointed as a Class II Director. The company also reported on compensatory arrangements for its named executive officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and executive compensation, which are routine corporate governance matters.
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan Leff (person) — Appointed Class II Director
- September 16, 2024 (date) — Effective date of board change
FAQ
Who was appointed to the board of directors at Dianthus Therapeutics?
Dr. Jonathan Leff was appointed as a Class II Director.
When was the board appointment effective?
The appointment was effective as of September 16, 2024.
What other information is disclosed in this 8-K filing?
The filing also covers the election of directors and compensatory arrangements of certain officers.
What is the state of incorporation for Dianthus Therapeutics?
Dianthus Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Dianthus Therapeutics?
The principal executive offices are located at 7 Times Square, 43rd Floor, New York, New York, 10036.
Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-16 16:06:43
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M
- $40,000 — omano will receive cash compensation of $40,000 per year for his service on the Board,
- $5,000 — on the Board, and cash compensation of $5,000 per year for his service as a member of
Filing Documents
- dnth-20240916.htm (8-K) — 39KB
- 0000950170-24-106820.txt ( ) — 191KB
- dnth-20240916.xsd (EX-101.SCH) — 56KB
- dnth-20240916_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: September 16, 2024 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary